Literature DB >> 33011050

Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches.

Marisa Holubar1, Lina Meng2, William Alegria2, Stan Deresinski3.   

Abstract

Vancomycin and daptomycin are options for the initial treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Treatment options for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains include daptomycin, ceftaroline, and combination therapies. There is a critical need for high-level evidence from clinical trials to allow optimally informed decisions in the treatment of MRSA bacteremia.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bacteremia; Ceftaroline; Daptomycin; Endocarditis; MRSA; Methicillin; Staphylococcus aureus; Vancomycin

Mesh：

Substances：

Year:  2020        PMID： 33011050     DOI： 10.1016/j.idc.2020.04.003

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  5 in total

Review 1.  Pre-surgical Nasal Decolonization of Staphylococcus aureus: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2022-08-23

2.  Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-Resistant Staphylococcus aureus: A Network Meta-Analysis.

Authors:  Xiaonan Xu; Ni Lu; Pan Song; Mingzhen Zhou; Yuanxiao Li; Zirui Wang; Xin Gao
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

Review 3.  Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by Staphylococcus aureus: A Comprehensive Review of the Evidence.

Authors:  Daniele Roberto Giacobbe; Silvia Dettori; Silvia Corcione; Antonio Vena; Chiara Sepulcri; Alberto Enrico Maraolo; Francesco Giuseppe De Rosa; Matteo Bassetti
Journal:  Infect Drug Resist       Date:  2022-04-22       Impact factor: 4.177

4.  Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections in Critically Ill Patients: Focus on Novel Infusion Mode.

Authors:  Xiangqing Song; Mi Han
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

5.  QKI degradation in macrophage by RNF6 protects mice from MRSA infection via enhancing PI3K p110β dependent autophagy.

Authors:  Dongsheng Zhai; Wenwen Wang; Zichen Ye; Ke Xue; Guo Chen; Sijun Hu; Zhao Yan; Yanhai Guo; Fang Wang; Xubo Li; An Xiang; Xia Li; Zifan Lu; Li Wang
Journal:  Cell Biosci       Date:  2022-09-10       Impact factor: 9.584
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.